Ranibizumab (anti-VEGF)  (Synonyms: RG-6321 (anti-VEGF))

Ranibizumab (RG-6321) (anti-VEGF) is a humanized anti-VEGF monoclonal antibody fragment and can recognize all VEGF-A isoforms (VEGF110, VEGF121, and VEGF165)^[1]. Ranibizumab (anti-VEGF) slows vision loss in vivo and is used for wet age-related macular degeneration (AMD) research^[1].

Fab-G1-kappa

Human

VEGFA

Ranibizumab (RG-6321) is a humanized anti-VEGF monoclonal antibody fragment (IgG antigen-binding fragment (Fab-Y0317)^[2]. Ranibizumab (0.0625-0.25 mg/ml; 72 hours) results in increased necrosis and apoptosis at in rat retinal cell cultures^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Studies in monkeys demonstrates that after a single intravitreal administration, Ranibizumab can distribute rapidly to the retina (6-24 h). Ranibizumab can rapidly penetrate through the retina to reach the choroid, just 1 h after intravitreal administration in rabbits^[1].
In a study comparing the pharmacokinetics of 0.5 mg of intravitreal Ranibizumab with 1.25 mg of intravitreal Bevacizumab in the rabbit, the vitreous half-life of Ranibizumab is 2.88 days, shorter than the Bevacizumab half-life of 4.32 days. Peak concentrations in the aqueous humor of the treated eye at 3 days following treatment are 37.7 μg/ml for Bevacizumab and 17.9 μg/ml for Ranibizumab, respectively^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

7422  [NCBI]

P15692

ELISA, FACS, Functional assay

Unconjugated

The product can be reconstituted/diluted with sterile PBS or saline.

49.19 kDa

347396-82-1

Liquid

Colorless to light yellow

[Ranibizumab (anti-VEGF)]

Shipping with dry ice.

Please refer to the lot-specific COA for specific buffer information.

Please store the product under the recommended conditions in the Certificate of Analysis.

• 
  Fab-G1-kappa

• 
  Immobilized VEGFA-FC can bind Ranibizumab (anti-VEGF). The EC₅₀ for this effect is 10.14 ng/mL.
• 
  Flow cytometric analysis of 1X10⁶ Hela cells with Ranibizumab (anti-VEGF) (HY-P9951A, red). Cells were fixed with 4% paraformaldehyde and permeabilised with 90% methanol. Then stained with the primary antibody at 1/200 dilution for an hour at 4℃. Alexa Fluor 488-conjugated AffiniPure Goat Anti-Human IgG H&L (HY-P83776) was used as the secondary antibody at 1/1,000 dilution for 30 minutes at 4℃. Human IgG1 kappa (HY-P99001, blue) was used as the isotype control, cells without incubation with primary antibody were used as the unlabeled control (black).

• [1]. Mustafa Şahiner, et al. The Effects of Anti-Vascular Endothelial Growth Factor Drugs on Retinal Pigment Epithelial Cell Culture. Turk J Ophthalmol. 2018 Aug;48(4):190-195.  [Content Brief]

  [2]. K J Kim, et al. The vascular endothelial growth factor proteins: identification of biologically relevant regions by neutralizing monoclonal antibodies. Growth Factors. 1992;7(1):53-64.  [Content Brief]

  [3]. Richard Filek, et al. Safety of anti-VEGF treatments in a diabetic rat model and retinal cell culture. Clin Ophthalmol. 2019 Jul 1;13:1097-1114.  [Content Brief]